SCHEMBL10107494

SCHEMBL10107494

COc1ncccc1C(=O)NC1CCN(Cc2ccccc2)CC1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC6A12 P48065 2/20 0.66
POLB P06746 1/20 0.65
MEN1 O00255 1/20 0.62
KMT2A Q03164 1/20 0.62
SIGMAR1 Q99720 2/20 0.62
ACKR3 P25106 1/20 0.61
MCHR1 Q99705 1/20 0.61
DRD4 P21917 4/20 0.60
CNR2 P34972 3/20 0.60
CNR1 P21554 2/20 0.60
DRD2 P14416 2/20 0.59
DRD3 P35462 2/20 0.59
CYP1A2 P05177 1/20 0.59
CYP3A4 P08684 1/20 0.59
ADRA2A P08913 1/20 0.59
CYP2D6 P10635 1/20 0.59
CYP2C9 P11712 1/20 0.59
ADRA2B P18089 1/20 0.59
ADRA2C P18825 1/20 0.59
ACHE P22303 1/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1753367 0.94 DRD4 (0.64) SLC6A12POLBSIGMAR1MCHR1DRD4
SCHEMBL10107601 0.83 SLC6A12 (0.83) SLC6A12POLBMEN1KMT2ASIGMAR1
SCHEMBL10107610 0.81 POLB (0.62) SLC6A12POLBMEN1KMT2ASIGMAR1
SCHEMBL14214884 0.80 MEN1 (0.72) SLC6A12POLBMEN1KMT2ASIGMAR1
SCHEMBL7239441 0.78 CCR3 (0.72) SLC6A12POLBMEN1KMT2ASIGMAR1
SCHEMBL10017943 0.78 SIGMAR1 (0.59) SLC6A12POLBMEN1KMT2ASIGMAR1
SCHEMBL14205010 0.78 POLB (0.58) POLBMEN1KMT2ASIGMAR1MCHR1
SCHEMBL7364615 0.77 SIGMAR1 (0.64) SLC6A12POLBMEN1KMT2ASIGMAR1
SCHEMBL5583755 0.77 SLC6A12 (0.61) SLC6A12POLBMEN1KMT2ASIGMAR1
SCHEMBL3959130 0.77 SIGMAR1 (0.73) SLC6A12POLBMEN1KMT2ASIGMAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8114880-B2 Piperidine or piperazine substituted tetrahydro-naphthalene-1-carboxylic acid MTP inhibiting compounds JANSSEN PHARMACEUTICA N.V. (BE) 2012-02-14 US disclosed
US-8114880-B2 Piperidine or piperazine substituted tetrahydro-naphthalene-1-carboxylic acid MTP inhibiting compounds JANSSEN PHARMACEUTICA N.V. (BE) 2012-02-14 US disclosed
US-20090325980-A1 PIPERIDINE OR PIPERAZINE SUBSTITUTED TETRAHYDRO-NAPHTHALENE-1-CARBOXYLIC ACID MTP INHIBITING COMPOUNDS JANSSEN PHARMACEUTICA N.V. (BE) 2009-12-31 US disclosed
US-20090325980-A1 PIPERIDINE OR PIPERAZINE SUBSTITUTED TETRAHYDRO-NAPHTHALENE-1-CARBOXYLIC ACID MTP INHIBITING COMPOUNDS JANSSEN PHARMACEUTICA N.V. (BE) 2009-12-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090325980-A1 PIPERIDINE OR PIPERAZINE SUBSTITUTED TETRAHYDRO-NAPHTHALENE-1-CARBOXYLIC ACID MTP INHIBITING COMPOUNDS PNLIP, APOB, LIPC SLC6A12 4389/4885POLB 2097/4885MEN1 4057/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.